HRP20141048T1 - Spojevi, pripravci i metode - Google Patents
Spojevi, pripravci i metode Download PDFInfo
- Publication number
- HRP20141048T1 HRP20141048T1 HRP20141048TT HRP20141048T HRP20141048T1 HR P20141048 T1 HRP20141048 T1 HR P20141048T1 HR P20141048T T HRP20141048T T HR P20141048TT HR P20141048 T HRP20141048 T HR P20141048T HR P20141048 T1 HRP20141048 T1 HR P20141048T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- pyridyl
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 8
- 238000000034 method Methods 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 9
- 208000019622 heart disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- QMQQPEHYAUOSMX-HNNXBMFYSA-N 1-[3-[(1s)-1-(4-acetylpiperazin-1-yl)ethyl]-2-fluorophenyl]-3-(6-methylpyridin-3-yl)urea Chemical compound N1([C@@H](C)C=2C(=C(NC(=O)NC=3C=NC(C)=CC=3)C=CC=2)F)CCN(C(C)=O)CC1 QMQQPEHYAUOSMX-HNNXBMFYSA-N 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JGCZESAGTZRSNH-UHFFFAOYSA-N ethyl 4-[[4-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1CC1=CC=C(F)C(NC(=O)NC=2C=NC(C)=CC=2)=C1 JGCZESAGTZRSNH-UHFFFAOYSA-N 0.000 claims 1
- NWJFYQGYSWNATK-HNNXBMFYSA-N methyl 4-[(1s)-1-[3-fluoro-5-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCN1[C@@H](C)C1=CC(F)=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1 NWJFYQGYSWNATK-HNNXBMFYSA-N 0.000 claims 1
- POGZGXAPKXAXJV-UHFFFAOYSA-N methyl 4-[[3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1 POGZGXAPKXAXJV-UHFFFAOYSA-N 0.000 claims 1
- SYVYFQFEFVZGJR-UHFFFAOYSA-N methyl 4-[[3-fluoro-5-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCN1CC1=CC(F)=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1 SYVYFQFEFVZGJR-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (6)
1. Spoj izabran od:
i) Metil 4-[(3-fluoro-5-{[(6-metil(3-piridil))amino]karbonilamino}-fenil)metil]piperazin karboksilat
[image]
ili njegova farmaceutski prihvatljiva sol;
ii) etil 4-[(4-fluoro-3-{[(6-metil(3-piridil))amino]karbonilamino}fenil)-metil]piperazinkarboksilat
[image]
ili njegova farmaceutski prihvatljiva sol;
iii) metil 4-[(2-fluoro-3-{[(6-metil(3-piridil))amino]karbonilamino}-fenil)metil]piperazinkarboksilat
[image]
ili njegova farmaceutski prihvatljiva sol;
iv) metil 4-[(3-{[(6-metil-3-piridil)amino]karbonilamino}fenil)-metil]piperazinkarboksilat
[image]
ili njegova farmaceutski prihvatljiva sol; i
v) metil 4-[(1S)-1-(5-fluoro-3-{[(6-metil(3-piridil))amino]karbonilamino}-fenil)etil]piperazinkarboksilat
[image]
ili njegova farmaceutski prihvatljiva sol; i
vi) N-{3-[(1S)-1-(4-acetilpiperazinil)etil]-2-fluorofenil}[(6-metil(3-piridil))amino]karboksamid
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, koji je metil 4-[(2-fluoro-3-{[(6-metil(3-piridil))amino]karbonilamino}-fenil)metil]piperazinkarboksilat
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Farmaceutski pripravak koji sadrži farmaceutski prihvatljiv ekscipijent, nosač ili adjuvans i spoj prema zahtjevu 1 ili zahtjevu 2, ili njihovu farmaceutski prihvatljivu sol.
4. Spoj ili farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3 za upotrebu u postupku liječenja srčanih oboljenja kod sisavaca, koji postupak obuhvaća primjenu na sisavca, kome je to potrebno, terapeutski efikasne količine spoja prema zahtjevu 1 ili zahtjevu 2, ili njegove farmaceutski prihvatljive soli, ili farmaceutskog pripravka prema zahtjevu 3.
5. Spoj ili farmaceutski pripravak za upotrebu prema zahtjevu 4, pri čemu je srčano oboljenje akutno ili dekompenzirano kongestivno zatajenje srca ili kronično kongestivno zatajenje srca.
6. Spoj ili farmaceutski pripravak za upotrebu prema zahtjevu 4, pri čemu je srčano oboljenje sistolična disfunkcija srca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58119704P | 2004-06-17 | 2004-06-17 | |
PCT/US2005/021100 WO2006009726A2 (en) | 2004-06-17 | 2005-06-16 | Substituted urea derivatives for treating cardiac diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20141048T1 true HRP20141048T1 (hr) | 2015-01-02 |
Family
ID=35785669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20141048TT HRP20141048T1 (hr) | 2004-06-17 | 2014-10-30 | Spojevi, pripravci i metode |
Country Status (33)
Country | Link |
---|---|
US (12) | US8110595B2 (hr) |
EP (2) | EP2862859B1 (hr) |
JP (2) | JP5080970B2 (hr) |
KR (1) | KR101276136B1 (hr) |
CN (1) | CN101035525A (hr) |
AR (1) | AR053405A1 (hr) |
AU (1) | AU2005264988B2 (hr) |
BR (1) | BRPI0512193B8 (hr) |
CA (1) | CA2570999C (hr) |
CY (1) | CY1115716T1 (hr) |
DK (2) | DK1765327T3 (hr) |
EA (1) | EA016138B1 (hr) |
EC (1) | ECSP077180A (hr) |
ES (2) | ES2522579T3 (hr) |
HK (2) | HK1101060A1 (hr) |
HR (1) | HRP20141048T1 (hr) |
IL (1) | IL180026A (hr) |
MA (1) | MA28738B1 (hr) |
ME (1) | ME01942B (hr) |
MX (1) | MXPA06014495A (hr) |
MY (1) | MY144470A (hr) |
NO (1) | NO340030B1 (hr) |
NZ (1) | NZ552404A (hr) |
PE (1) | PE20060438A1 (hr) |
PL (2) | PL1765327T3 (hr) |
PT (1) | PT1765327E (hr) |
RS (1) | RS53600B1 (hr) |
RU (1) | RU2410384C2 (hr) |
SG (1) | SG149027A1 (hr) |
SI (1) | SI1765327T1 (hr) |
TW (1) | TWI359812B (hr) |
WO (1) | WO2006009726A2 (hr) |
ZA (1) | ZA200700351B (hr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495337B1 (en) * | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
MXPA05007513A (es) * | 2003-01-14 | 2005-09-21 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
BRPI0512193B8 (pt) * | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
EP1824843A2 (en) * | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2008523071A (ja) * | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ, インコーポレイテッド | Mapキナーゼの尿素インヒビター |
US7538223B2 (en) * | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
EP1959947A2 (en) * | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
WO2007078815A2 (en) * | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP2009522363A (ja) * | 2006-01-04 | 2009-06-11 | ローカス ファーマシューティカルズ、インク. | プロテインキナーゼの阻害剤 |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
KR20140031899A (ko) | 2011-04-20 | 2014-03-13 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 최소의 각 의존성을 갖는 표시 장치들 및 이미징을 위한 스펙트럼 필터링 |
CN102288601B (zh) * | 2011-05-16 | 2012-12-12 | 中国药科大学 | 一种肌球蛋白atp酶活性微量测定方法及其应用 |
AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
US9709649B2 (en) * | 2013-02-08 | 2017-07-18 | Regents Of The University Of Minnesota | System and method for assessing adenosine triphosphate hydrolysis rate using double saturation transfer magnetic resonance imaging and spectroscopy |
ES2733340T3 (es) | 2013-03-14 | 2019-11-28 | Amgen Inc | Compuestos heterocíclicos y sus usos |
PL2970123T3 (pl) * | 2013-03-14 | 2020-03-31 | Amgen Inc. | Sól omekamtywu mekarbilu i sposób otrzymywania soli |
US9547107B2 (en) | 2013-03-15 | 2017-01-17 | The Regents Of The University Of Michigan | Dye and pigment-free structural colors and angle-insensitive spectrum filters |
WO2015142001A2 (ko) * | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
PE20171511A1 (es) * | 2015-01-22 | 2017-10-20 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) |
KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
HUE053603T2 (hu) * | 2016-10-10 | 2021-07-28 | Basf Se | Katalizátor módosítása alkálifém, alkáliföldfém vagy ritkaföldfém ionokkal nitrovegyületek folytonos folyadék fázisú hidrogénezése során |
US10256925B2 (en) * | 2017-01-19 | 2019-04-09 | Samsung Electronics Co., Ltd. | Methods and wireless communication systems for wireless re-calibration of RF components of communication devices |
IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
WO2019006235A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
AU2018332887B2 (en) | 2017-09-13 | 2022-12-08 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
CA3087283A1 (en) * | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
WO2020005887A1 (en) | 2018-06-26 | 2020-01-02 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
EP3820851A1 (en) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
AU2019321573A1 (en) | 2018-08-17 | 2021-03-04 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス, インコーポレイテッド | 心筋サルコメア阻害剤 |
US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
US20220411374A1 (en) * | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
EP4243825A1 (en) | 2020-11-12 | 2023-09-20 | Amgen Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
BR112023018095A2 (pt) | 2021-03-10 | 2023-12-12 | Amgen Inc | Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo |
WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US397782A (en) * | 1889-02-12 | Plunger water-closet | ||
NL254871A (hr) | 1959-08-14 | |||
GB1339764A (en) | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
US3939169A (en) | 1971-03-29 | 1976-02-17 | Imperial Chemical Industries Limited | Alkylene bis(pyridiniumareylene quaternary salts) |
DE2942930A1 (de) | 1979-10-24 | 1981-05-27 | Basf Ag, 6700 Ludwigshafen | Substituierte harnstoffe, deren herstellung und verwendung als herbizide |
CA1185974A (en) | 1981-12-03 | 1985-04-23 | Adolf Parg | 1,3,5-triazinones and their use for controlling undesirable plant growth |
DE3147879A1 (de) | 1981-12-03 | 1983-06-16 | Basf Ag, 6700 Ludwigshafen | 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
RO93481B (ro) | 1983-03-29 | 1988-01-01 | Fmc Corporation | Compozitie solida pentru reglarea cresterii plantelor |
US4787931A (en) | 1984-03-06 | 1988-11-29 | Fmc Corporation | N-phenyl-N'-(pyridinyl-N-oxide)urea plant regulators |
US4672066A (en) | 1985-04-22 | 1987-06-09 | Hoffmann-La Roche Inc. | Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids |
GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
GEP20001968B (en) | 1992-01-21 | 2000-03-05 | Glaxo Spa | Arilthio Compounds as Antibacterial and Antiviral Agents |
US6001860A (en) | 1992-05-28 | 1999-12-14 | Pfizer Inc. | N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT) |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
EP0634402A1 (en) * | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
KR970706242A (ko) | 1994-10-04 | 1997-11-03 | 후지야마 아키라 | 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors) |
DE69533174T2 (de) | 1994-10-27 | 2004-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten |
US6010026A (en) | 1994-11-22 | 2000-01-04 | Aluminum Company Of America | Assembly of aluminum can and threaded sleeve |
US5556969A (en) | 1994-12-07 | 1996-09-17 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
GB9504361D0 (en) | 1995-03-04 | 1995-04-26 | Glaxo Spa | Heterocyclic compounds |
GB9511355D0 (en) | 1995-06-06 | 1995-08-02 | Fujisawa Pharmaceutical Co | Urea derivatives |
US5972975A (en) | 1995-12-08 | 1999-10-26 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
WO1998003492A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
IT1284198B1 (it) | 1996-07-30 | 1998-05-08 | Beniamino Anzalone | Carne vegetale |
US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
AUPO390996A0 (en) | 1996-11-29 | 1996-12-19 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives |
JP2002241368A (ja) | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
WO1998041510A1 (fr) | 1997-03-14 | 1998-09-24 | Shionogi & Co., Ltd. | Nouveaux derives du benzolactame et compositions medicamenteuses les contenant |
AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
CA2291065C (en) | 1997-05-23 | 2010-02-09 | Bayer Corporation | Raf kinase inhibitors |
PT1019040E (pt) | 1997-05-23 | 2005-01-31 | Bayer Pharmaceuticals Corp | Inibicao da actividade de p38-quinase por meio de arilureias |
WO1999023090A1 (en) | 1997-11-05 | 1999-05-14 | Choongwae Pharma Corporation | Novel genipin derivative having liver protection activity |
EP1049664B1 (en) | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
CA2315720A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
KR100571588B1 (ko) | 1997-12-22 | 2006-04-17 | 바이엘 코포레이션 | 치환 헤테로시클릭 우레아를 이용한 raf 키나제의 억제 |
EP1042305B1 (en) | 1997-12-22 | 2005-06-08 | Bayer Pharmaceuticals Corp. | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
CA2334298C (en) | 1998-06-08 | 2008-01-08 | Schering Corporation | Neuropeptide y5 receptor antagonists |
US6407124B1 (en) | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
JP3594317B2 (ja) * | 1998-08-11 | 2004-11-24 | 住友製薬株式会社 | ナフチリジン誘導体 |
JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
AU3707600A (en) | 1999-03-01 | 2000-09-21 | Regents Of The University Of California, The | Thiacrown polymers for removal of mercury from waste streams |
DE19921498A1 (de) | 1999-05-08 | 2000-11-16 | Clariant Gmbh | Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen |
ES2253233T3 (es) | 1999-07-09 | 2006-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Procedimiento para sintesis de compuestos de urea heteroaril sustituidos. |
ES2251395T3 (es) | 1999-07-26 | 2006-05-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de biarilureas. |
EP1229010A1 (en) | 1999-10-01 | 2002-08-07 | Japan Energy Corporation | Novel diarylamide derivatives and use thereof as medicines |
ES2292488T3 (es) | 1999-11-16 | 2008-03-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Derivados de la urea, como agentes antiinflamatorios. |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
JP2001278886A (ja) * | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
WO2001098269A2 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
GB0015904D0 (en) | 2000-06-28 | 2000-08-23 | Hoffmann La Roche | Inhibitors of HPV E1 helicase enzyme |
US6573267B2 (en) * | 2000-06-30 | 2003-06-03 | Ortho-Mcneil Pharmaceutical, Inc. | Useful aroyl aminoacyl pyrrole compounds |
ES2291329T3 (es) | 2000-07-18 | 2008-03-01 | Dainippon Sumitomo Pharma Co., Ltd. | Inhibidores de la recaptacion de serotonina. |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
EP1360173A2 (en) | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
JP2002220338A (ja) | 2001-01-26 | 2002-08-09 | Banyu Pharmaceut Co Ltd | ビアリールウレア化合物又はその塩を有効成分として含有するCdk4及び/又はCdk6阻害剤 |
GB0117950D0 (en) | 2001-02-16 | 2001-09-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
ATE355272T1 (de) | 2001-04-20 | 2006-03-15 | Bayer Pharmaceuticals Corp | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
EP1392661A1 (en) | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
WO2002099388A2 (en) | 2001-06-07 | 2002-12-12 | Merck & Co., Inc. | Benzodiazepine bradykinin antagonists |
ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
DE10134482A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
US7297708B2 (en) | 2001-09-06 | 2007-11-20 | Bristol-Myers Squibb Company | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands |
CA2460149A1 (en) | 2001-09-12 | 2003-03-27 | Kaken Pharmaceutical Co., Ltd. | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
US7320126B2 (en) * | 2001-11-06 | 2008-01-15 | Sandisk Corporation | Implementation of in system programming to update firmware on memory cards |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
AU2002367023A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
US20030207872A1 (en) | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7408067B2 (en) | 2002-01-17 | 2008-08-05 | Merck + Co., Inc. | Aza-cyclic compounds as modulators of acetylcholine receptors |
US7148236B2 (en) | 2002-01-17 | 2006-12-12 | Merck & Co., Inc. | Modulators of acetylcholine receptors |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
DE10208986A1 (de) | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase |
JP4471262B2 (ja) | 2002-03-07 | 2010-06-02 | 株式会社エス・ディー・エス バイオテック | 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤 |
TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
EA007328B1 (ru) | 2002-03-28 | 2006-08-25 | Апплайд Резеч Системз Арс Холдинг Н. В. | Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f |
US20050182040A1 (en) | 2002-04-03 | 2005-08-18 | Naonori Imazaki | Benzamide derivatives |
US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
JP4384918B2 (ja) | 2002-04-18 | 2009-12-16 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとして有用な(1−4−ピペリジニル)ベンズイミダゾール誘導体 |
JP2005529890A (ja) | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
US20060052600A1 (en) | 2002-05-17 | 2006-03-09 | Nielsen Simone F | Amino-functional chalcones |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
JP4326468B2 (ja) | 2002-06-24 | 2009-09-09 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとして有用なインドール誘導体 |
EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
AU2003281855A1 (en) | 2002-07-31 | 2004-02-23 | Schering Aktiengesellschaft | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
GB0218147D0 (en) | 2002-08-05 | 2002-09-11 | Oxford Glycosciences Uk Ltd | Novel compounds |
WO2004019958A1 (ja) | 2002-08-27 | 2004-03-11 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
KR101088922B1 (ko) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
US6915814B2 (en) * | 2002-09-04 | 2005-07-12 | Dara Cheng | Transparent pipe trap with means of enhancing the biodegradation of sink effluents |
BR0314201A (pt) | 2002-09-10 | 2005-07-12 | Pfizer Prod Inc | Compostos diazabicìclicos úteis no tratamento de doenças do cns e outros distúrbios |
ATE361739T1 (de) | 2002-10-29 | 2007-06-15 | Oreal | Haarpflegemittel enthaltend eine styrylpyrazole verbindung |
MXPA05007513A (es) | 2003-01-14 | 2005-09-21 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
AU2003902073A0 (en) | 2003-05-01 | 2003-05-15 | Kevin Raymond Deguara | A lighting substrate |
ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
JPWO2004101529A1 (ja) | 2003-05-19 | 2006-07-13 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
GB0316915D0 (en) * | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
RU2006122853A (ru) | 2003-11-28 | 2008-01-10 | Новартис АГ (CH) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
EP1768575B1 (en) | 2004-06-18 | 2019-01-16 | Medtronic, Inc. | Devices for occlusion of an atrial appendage |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959947A2 (en) | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7672247B2 (en) * | 2006-02-23 | 2010-03-02 | International Business Machines Corporation | Evaluating data processing system health using an I/O device |
-
2005
- 2005-06-16 BR BRPI0512193A patent/BRPI0512193B8/pt active IP Right Grant
- 2005-06-16 PL PL05761304T patent/PL1765327T3/pl unknown
- 2005-06-16 EA EA200700058A patent/EA016138B1/ru not_active IP Right Cessation
- 2005-06-16 JP JP2007516674A patent/JP5080970B2/ja active Active
- 2005-06-16 PT PT57613044T patent/PT1765327E/pt unknown
- 2005-06-16 SI SI200531908T patent/SI1765327T1/sl unknown
- 2005-06-16 KR KR1020077001142A patent/KR101276136B1/ko active IP Right Grant
- 2005-06-16 EP EP14180082.1A patent/EP2862859B1/en active Active
- 2005-06-16 RU RU2007101619/04A patent/RU2410384C2/ru active
- 2005-06-16 AU AU2005264988A patent/AU2005264988B2/en active Active
- 2005-06-16 ES ES05761304.4T patent/ES2522579T3/es active Active
- 2005-06-16 MX MXPA06014495A patent/MXPA06014495A/es active IP Right Grant
- 2005-06-16 RS RSP20140518 patent/RS53600B1/en unknown
- 2005-06-16 ES ES14180082.1T patent/ES2686357T3/es active Active
- 2005-06-16 CN CNA2005800280711A patent/CN101035525A/zh active Pending
- 2005-06-16 US US11/630,062 patent/US8110595B2/en active Active
- 2005-06-16 PL PL381801A patent/PL216049B1/pl unknown
- 2005-06-16 DK DK05761304.4T patent/DK1765327T3/da active
- 2005-06-16 NZ NZ552404A patent/NZ552404A/en unknown
- 2005-06-16 EP EP05761304.4A patent/EP1765327B1/en active Active
- 2005-06-16 US US11/155,940 patent/US7507735B2/en active Active
- 2005-06-16 SG SG200809263-7A patent/SG149027A1/en unknown
- 2005-06-16 TW TW094119915A patent/TWI359812B/zh active
- 2005-06-16 ME MEP-2014-137A patent/ME01942B/me unknown
- 2005-06-16 WO PCT/US2005/021100 patent/WO2006009726A2/en active Application Filing
- 2005-06-16 DK DK14180082.1T patent/DK2862859T3/en active
- 2005-06-16 MY MYPI20052761A patent/MY144470A/en unknown
- 2005-06-16 CA CA2570999A patent/CA2570999C/en active Active
- 2005-06-17 PE PE2005000695A patent/PE20060438A1/es active IP Right Grant
- 2005-06-17 AR ARP050102494A patent/AR053405A1/es active IP Right Grant
-
2006
- 2006-12-12 IL IL180026A patent/IL180026A/en active IP Right Grant
-
2007
- 2007-01-12 ZA ZA200700351A patent/ZA200700351B/xx unknown
- 2007-01-15 NO NO20070257A patent/NO340030B1/no unknown
- 2007-01-17 EC EC2007007180A patent/ECSP077180A/es unknown
- 2007-01-17 MA MA29616A patent/MA28738B1/fr unknown
- 2007-08-13 HK HK07108757.9A patent/HK1101060A1/xx unknown
-
2008
- 2008-09-25 US US12/238,313 patent/US8101617B2/en active Active
-
2011
- 2011-12-06 JP JP2011266808A patent/JP2012097093A/ja active Pending
- 2011-12-30 US US13/341,413 patent/US8513257B2/en active Active
-
2013
- 2013-07-19 US US13/946,353 patent/US8871769B2/en active Active
-
2014
- 2014-09-18 US US14/489,705 patent/US9150564B2/en active Active
- 2014-10-30 HR HRP20141048TT patent/HRP20141048T1/hr unknown
- 2014-11-06 CY CY20141100923T patent/CY1115716T1/el unknown
-
2015
- 2015-08-27 US US14/837,201 patent/US9643925B2/en active Active
- 2015-10-22 HK HK15110370.2A patent/HK1209729A1/xx unknown
-
2017
- 2017-04-06 US US15/480,618 patent/US10035770B2/en active Active
-
2018
- 2018-06-28 US US16/021,418 patent/US10385023B2/en active Active
-
2019
- 2019-07-02 US US16/459,754 patent/US10975034B2/en active Active
-
2021
- 2021-03-12 US US17/200,174 patent/US20210198203A1/en not_active Abandoned
- 2021-10-22 US US17/452,025 patent/US20220185779A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
US10550066B2 (en) | Substituted aromatic compounds and related method for the treatment of fibrosis | |
DE602004011511T2 (de) | N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes | |
JP2021176846A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
KR102062824B1 (ko) | 2-[6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸]-4-플루오로-벤조니트릴의 용도 | |
KR101423347B1 (ko) | 다발성 경화증의 치료 또는 예방제 | |
CA2622472C (en) | Dipeptidyl peptidase inhibitors for treating diabetes | |
JP2004525179A5 (hr) | ||
JP2014502979A5 (hr) | ||
JP2009500443A5 (hr) | ||
ATE330585T2 (de) | Behandlung von atemerkrankungen | |
JP2005509024A5 (hr) | ||
KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
JP2008513516A5 (hr) | ||
JP2008513510A5 (hr) | ||
JP2010514696A (ja) | 心血管症状の低減 | |
JP2014129406A (ja) | TNFαシグナル伝達のモジュレータ | |
CN101171234B (zh) | 二氢吡啶衍生物 | |
JP2019531346A (ja) | 甲状腺関連副作用を低下させる方法 | |
WO2002017915A1 (en) | Benzylidene thiazolidinediones and their use as antimycotic agents | |
JP2005511656A5 (hr) | ||
JP2007525533A5 (hr) | ||
US7273883B2 (en) | Prostaglandin EP4 antagonist | |
JP2004532828A5 (hr) | ||
WO2004098612A2 (en) | Calcitriol analogs of uses thereof |